The insufficient levels of CBL have been identified as a factor contributing to the development of chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC), which is attributed largely to the stress-induced activation of EGFR (epidermal growth factor receptor). The gene discussed is CBL; the disease is pancreatic ductal adenocarcinoma.